Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|October 26, 2009

Quintiles Partners with UK Trust and University for Phase I Unit

London, UK

Two of the UK’s leading institutions - Guy’s and St Thomas’ NHS Foundation Trust and King’s College London - have signed a collaborative agreement with Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. This collaboration is a step towards increasing efficiency in early stage clinical research.
 
As part of the agreement, Quintiles has commissioned a research facility with 30 beds, for both patients and healthy volunteers involved in research, on the 14th floor of Guy’s Hospital in central London. The facility, to be completed in early 2010, will now be known as the Quintiles Drug Research Unit at Guy’s Hospital. The facility significantly increases Quintiles’ capacity to conduct proof-of-concept programmes that help biopharmaceutical companies develop medicines.


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.